Abstract
Cleavage of the MUC1 glycoprotein yields two subunits, an extracellular alpha-subunit bound to a smaller transmembrane beta-subunit. Monoclonal antibodies (mAbs) directed against the MUC1 alpha–beta junction comprising the SEA domain, a stable cell-surface moiety, were generated. Sequencing of all seven anti-SEA domain mAbs showed that they clustered into four groups and sequences of all groups are presented here. mAb DMB5F3 with picomolar affinity for the MUC1 SEA target was selected for further evaluation. Immunohistochemical staining of a series of malignancies with DMB5F3 including lung, prostate, breast, colon, and pancreatic carcinomas revealed qualitative and qualitative differences between MUC1 expression on normal versus malignant cells: DMB5F3 strongly stained malignant cells in a near-circumferential pattern, whereas MUC1 in normal pancreatic and breast tissue showed only weak apical positivity of ductal/acinar cells. Humanized chimeric DMB5F3 linked to ZZ-PE38 (ZZ IgG-binding protein fused to Pseudomonas exotoxin) induced vigorous cytotoxicity of MUC1+ malignant cells in vitro. The intensity of cell killing correlated with the level of MUC1 expression by the target cell, suggesting a MUC1 expression threshold for cell killing. MUC1+ Colo357 pancreatic cancer cells xenotransplanted into nude and SCID mice models were treated with the chDMB5F3:ZZ-PE38 immunocomplex. In both transplant models, chDMB5F3:ZZ-PE38 exhibited significant in vivo anti-tumor activity, suppressing up to 90% of tumor volume in the SCID model compared with concomitant controls. The efficacy of chDMB5F3:ZZ-PE38 immunotoxin in mediating tumor killing both in vitro and in vivo strongly suggests a clinical role for anti-MUC1 SEA antibody in the treatment of MUC1-expressing malignancies.
Similar content being viewed by others
References
Nath S, Mukherjee P (2014) MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 20:332–342
Deng J, Wang L, Chen H, Li L, Ma Y, Ni J, Li Y (2013) The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Rev 32:535–551
Rahn JJ, Dabbagh L, Pasdar M, Hugh JC (2001) The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91:1973–1982
Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH, Mandel U, Clausen H, Yu F, Hollingsworth MA (2013) Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res 19:1981–1993
Krishn SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, Lo WC, Fan WT, Manne U, Batra SK (2016) Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett 374:304–314
Xu F, Liu F, Zhao H, An G, Feng G (2015) Prognostic significance of mucin antigen MUC1 in various human epithelial cancers: a meta-analysis. Medicine (Baltimore) 94:e2286
Cloosen S, Gratama J, van Leeuwen EB, Senden-Gijsbers BL, Oving EB, von Mensdorff-Pouilly S, Tarp MA, Mandel U, Clausen H, Germeraad WT, Bos GM (2006) Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol 135:513–516
Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Gregoire M, Pichinuk E, Rubinstein DB, Wreschner DH (2019) Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Exp Hematol 70:97–108
Rivalland G, Loveland B, Mitchell P (2015) Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Exp Opin Biol Ther 15:1773–1787
Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286–15293
Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J (1990) Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265:5573–5578
Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH (2005) The MUC1 SEA module is a self-cleaving domain. J Biol Chem 280:33374–33386
Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH (1994) Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett 356:130–136
Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A et al (1990) Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem 189:463–473
Macao B, Johansson DG, Hansson GC, Hard T (2006) Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 13:71–76
Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C (2016) A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur J Cancer 63:55–63
Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA, Miyazaki K, Kenemans P, Hilgers J (2000) Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumour Biol 21:197–210
Zhou D, Xu L, Huang W, Tonn T (2018) Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography: toward glycopeptide signature-guided therapy. Molecules 23:1326
Kimura T, Finn OJ (2013) MUC1 immunotherapy is here to stay. Exp Opin Biol Ther 13:35–49
Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M (2011) Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 17:6822–6830
Rubinstein DB, Karmely M, Ziv R, Benhar I, Leitner O, Baron S, Katz BZ, Wreschner DH (2006) MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res 66:11247–11253
Pichinuk E, Benhar I, Jacobi O, Chalik M, Weiss L, Ziv R, Sympson C, Karwa A, Smorodinsky NI, Rubinstein DB, Wreschner DH (2012) Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res 72:3324–3336
Rubinstein DB, Karmely M, Pichinuk E, Ziv R, Benhar I, Feng N, Smorodinsky NI, Wreschner DH (2009) The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing. Int J Cancer 124:46–54
Mazor Y, Barnea I, Keydar I, Benhar I (2007) Antibody internalization studied using a novel IgG binding toxin fusion. J Immunol Methods 321:41–59
Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154
Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH (2016) MUC1-ARF-A novel MUC1 protein that resides in the nucleus and is expressed by alternate reading frame translation of MUC1 mRNA. PLoS ONE 11:e0165031
Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH (2007) PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 13:7380–7387
Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226–243
Guo R, Guo W, Cao L, Liu H, Liu J, Xu H, Huang W, Wang F, Hong Z (2016) Fusion of an albumin-binding domain extends the half-life of immunotoxins. Int J Pharm 511:538–549
Tarp MA, Sorensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H (2007) Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17:197–209
Panchamoorthy G, Jin C, Raina D, Bharti A, Yamamoto M, Adeebge D, Zhao Q, Bronson R, Jiang S, Li L, Suzuki Y, Tagde A, Ghoroghchian PP, Wong KK, Kharbanda S, Kufe D (2018) Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight. https://doi.org/10.1172/jci.insight.99880
Scott AM, Allison JP, Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12:14
Finn OJ (2017) Human tumor antigens yesterday, today, and tomorrow, cancer. Immunol Res 5:347–354
Horm TM, Schroeder JA (2013) MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adhes Migr 7:187–198
Wong N, Major P, Kapoor A, Wei F, Yan J, Aziz T, Zheng M, Jayasekera D, Cutz JC, Chow MJ, Tang D (2016) Amplification of MUC1 in prostate cancer metastasis and CRPC development. Oncotarget 7:83115–83133
Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy ER, Sanders R, Sepulveda MA, Moores SL, Chiu ML (2015) Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor x c-MET bispecific antibody. J Biol Chem 290:24689–24704
Peat N, Gendler SJ, Lalani N, Duhig T, Taylor-Papadimitriou J (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52:1954–1960
Xu H, Gan L, Han Y, Da Y, Xiong J, Hong S, Zhao Q, Song N, Cai X, Jiang X (2019) Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process. RSC Adv 9:1909–1917
Janus A, Robak T (2019) Moxetumomab pasudotox for the treatment of hairy cell leukemia. Exp Opin Biol Ther 19:501–508
de Goeij BE, Lambert JM (2016) New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14–23
Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol 28:2085–2093
Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas MG, Dorywalska M, Farias S, Pios A, Lui V, Dushin R, Zhou D, Navaratnam T, Tran TT, Sutton J, Lindquist KC, Han B, Liu SH, Shelton DL, Pons J, Rajpal A (2015) Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33:694–696
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 15:333–348
Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J, Reis-Filho JS, Tutt A (2012) Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genom 13:619
Funding
Funded by Israel Cancer Association (Project 20112024) and Israel Science Foundation (Project 1167/10).
Author information
Authors and Affiliations
Contributions
EP, MC, IB, RGK, RZ, NIS, GH, CG, AB, AM, TG, DBR, and DHW contributed to the study conception and design. Material preparation, data collection, and analysis were performed by authors DHW, EP, MC, DBR, MC, AM, CG, AB, and NIS. The first draft of the manuscript was written by DHW, DBR and EP. EP, MC, IB, NIS, DBR, and DHW commented on the various versions of the manuscript and contributed to the actual writing and preparation of its final version. EP, MC, IB, RGK, RZ, NIS, GH, CG, AB, AM, TG, DBR, and DHW read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Daniel H. Wreschner and Daniel B. Rubinstein have ownership interest in BioModifying, LLC. All other authors declare that they have no conflict of interest.
Ethical Approval
Animal care and use Use of mice was done under supervision of the Tel Aviv University Institutional Animal Care and Use Committee (TAU-IACUC), Study Approval License number L-04-12-003. To ameliorate suffering including methods of killing, animal welfare and steps were all performed in accordance with regulations stipulated by TAU-IACUC. Samples used for immunohistochemical stainings These were procured from the Biomax tissue bank, see http://biomax.us. With all required approvals therein. Cell line authentication Short Tandem Repeat (STR) analysis (PowerPlexW 1.2 System, Promega, Fitchburg, WI), as described [45], was used to validate the human cell lines. STR profiles were matched with the German Collection of Microorganisms and Cell Cultures (DSMZ) database. Cell lines were obtained as gifts from Prof. I. Keydar.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Pichinuk, E., Chalik, M., Benhar, I. et al. In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. Cancer Immunol Immunother 69, 1337–1352 (2020). https://doi.org/10.1007/s00262-020-02547-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-020-02547-2